-
Company Insights
Innovation and Patenting activity of HUYA Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of HUYA Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GH-21 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GH-21 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GH-21 in Non-Small Cell Lung Cancer Drug Details: GH-21...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GH-21 in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GH-21 in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GH-21 in Head And Neck Squamous...
-
Thematic Analysis
NewMobile Gaming – Thematic Intelligence
Mobile Gaming Thematic Intelligence Report Overview The mobile gaming market is already bigger than the console and PC gaming markets combined. The growing maturity of streaming (supported by 5G), cloud gaming, and mobile esports, combined with the fact that mobile platforms are close to technological parity with PCs and consoles, means most gamers will embrace mobile gaming in the next few years. The mobile gaming thematic intelligence report provides an overview of the mobile gaming theme and identifies the key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tucidinostat in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tucidinostat in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tucidinostat in Non-Small Cell Lung Cancer Drug Details: Tucidinostat...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tucidinostat in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tucidinostat in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tucidinostat in Metastatic Melanoma Drug Details: Tucidinostat (Epidaza, Hiyasta) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tucidinostat in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tucidinostat in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tucidinostat in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tucidinostat in Anaplastic Large Cell Lymphoma (ALCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tucidinostat in Anaplastic Large Cell Lymphoma (ALCL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tucidinostat in Anaplastic Large Cell Lymphoma (ALCL) Drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CLN-978 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CLN-978 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CLN-978 in Follicular Lymphoma Drug Details: CLN-978 is under development for the...
-
Product Insights
Cutaneous Mycosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Cutaneous Mycosis - Drugs In Development, 2023’, provides an overview of the Cutaneous Mycosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cutaneous Mycosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...